VANCOUVER, BRITISH COLUMBIA
M Pharmaceutical, Inc. (CSE:MQ) (OTCQB:MPHMF) (FRANKFURT:T3F2), (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, today announced the engagement of Roy M. Kulick, MD as Clinical Development Advisor. Dr. Kulick will prepare clinical trial plans for the Company's lead product, Trimeo capsules for the treatment of obesity.
"I am pleased that Dr. Kulick has agreed to join M Pharmaceutical at this crucial time as we plan for the clinical development of Trimeo," said the Company's CEO, Matthew Lehman. "I believe his clinical development experience will prove beneficial to our growth plans."
Dr. Roy M. Kulick is an MBA-trained physician with a track record of success in clinical research, life sciences start-ups, and regulatory strategy. After receiving his MD from the University of Pennsylvania School of Medicine, Dr. Kulick has served in a number of academic and industry roles including Division Director at Cincinnati Children's Hospital; Executive Director of Schuman Associates IRB; Senior Scientist at the Proctor & Gamble Co., where he led clinical evaluation of weight management technologies; and Director of Clinical Research at Ethicon Endo-Surgery (a Johnson & Johnson Company). Currently, Dr. Kulick is an Entrepreneur-in-Residence at the University of Cincinnati Technology Accelerator for Commercialization and at the University of Louisville Coulter Translational Partnership as well as the Principal of ConneXion Life Sciences.
About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company acquired the exclusive rights to three technologies invented by Dr. Martin Mintchev at the University of Calgary: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.
M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.
+1 604 428 0511
© 2022 Canjex Publishing Ltd. All rights reserved.